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Abstract 
Although the Human Papillomavirus (HPV) vaccine has been approved and 
recommended by the FDA and other vaccine experts (ACIP, AAP, AAFP, and ACOG) for over a 
decade, the national uptake rate of the HPV vaccine has remained below the Healthy People 
2020 goal of 80% (OFPHP, 2018). In 2016, the clinic’s completion rate for the HPV series was 
only 27.7% among adolescents 11- to 13-years-old, which was not only below national targets, 
but also below the organization’s completion rate goal of 30.4%. Last year, in 2017, the 
Burlingame pediatric primary care clinic implemented the HPV Vaccination Improvement 
Project through the Pediatric Service Line and was able to increase their completion rates up to 
31.1%, which surpassed the previous year’s organizational goal. For this year, the most recent 
completion rate was 16.9% as of April and our current completion rate goal for this year is 
34.4%.  
This change project aims to increase the rates of HPV vaccine uptake in the pediatric 
primary care clinic through patient outreach and reminder/recall telephone calls and mailed 
letters. The quality improvement project was initially based on the 4 Pillars of Practice 
Transformation program, however, due to the limitations of this project, we have chosen to focus 
on just one strategy/intervention to improve HPV vaccine rates in the clinic.  
The project is planned to start July 9, 2018 and go until July 30, 2018. We will measure a 
combination of process, outcome and balancing measures, including HPV initiation and 
completion rates, number of HPV vaccines given and appointments scheduled as a result of 
patient outreach calls. Additionally, we will track “used opportunities to vaccinate”, missed 
opportunities to vaccinate and simultaneous vaccines given.  
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As a result of the outreach calls, we were able to schedule a total of 40 appointments. Out 
of the patients who came in for their appointments, 11 patients completed the HPV series and 
two patients initiated the HPV series; this led to an improvement of about 2%, which was less 
than our goal of 5-10% improvement. However, if all 40 patients who were scheduled as a result 
of the outreach calls came in to their appointments and received an HPV vaccine, then that 
would translate to an improvement rate of 7% which would meet our goal.  
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Improving Rates of HPV Immunization in the Pediatric Primary Care Setting 
Problem Description 
The Human Papillomavirus (HPV) is the most commonly sexually transmitted infection 
(STI); it is estimated that about 79 million Americans (in their late teens and early 20s) are 
infected with HPV (Centers for Disease Prevention and Control [CDC], 2017). Another 14 
million people become infected each year (CDC, 2017). In some cases, HPV resolves on its own 
and does not cause any long term health consequences. However, certain strains of HPV can 
cause genital warts or cancer. At any given time, it is estimated that about one in every 100 
sexually active adults in the United States (U.S.) has genital warts caused by HPV (CDC, 2017). 
HPV can also cause cervical cancer, as well as other cancers, including: cancer of the vulva, 
penis, anus, and oropharynx. Approximately 12,000 women in the U.S. will be diagnosed with 
cervical cancer every year, and 4,000 women will die from it (CDC, 2017).  
Although people can be tested for HPV, there is no way to determine which individuals 
will develop cancer or other HPV-related conditions (CDC, 2016). Unfortunately, the type of 
cancers caused by HPV do not usually show any obvious symptoms until it is at advanced stages, 
and by that point they are very serious and difficult to treat. Regular screening for cervical cancer 
can detect the earliest signs of this disease, but there aren’t any other diagnostic tools available to 
detect the other types of cancers caused by HPV. Consequently, it is necessary and (more 
effective) to prevent HPV infection through vaccination. HPV vaccines have been available and 
recommended by the U.S. Advisory Committee on Immunization Practices (ACIP) for 
adolescent girls since 2006, and for adolescent boys since 2011 (National Cancer Institute [NCI], 
2013).  
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Two years ago, in 2016, the CDC approved a reduction in the number of HPV doses 
required for adequate protection to two doses for adolescents 15 years of age and younger, 
reducing the amount office visits needed to complete the series (CDC, 2018a; California 
Emerging Infections Program, n.d.). Although the benefits of HPV vaccines are significant, and 
it is now easier to complete the HPV series, the uptake of this vaccine remains way below the 
target level. 
The pediatric primary care clinic in Burlingame started tracking HPV series initiation and 
completion rates in 2016. In 2016, there were 394 pediatric patients (between the ages of 11-13 
years old) who were eligible to start the HPV vaccination series; 109 of those patients completed 
the vaccination series, 102 patients started, but did not complete the series, and 183 patients did 
not start the series. This led to a completion rate of 27.7%, which was below the organization’s 
completion rate goal of 30.4%. This shortcoming led to the development and implementation of 
an HPV Vaccination Improvement Project on behalf of the Pediatric Service Line.  
In an attempt to increase HPV vaccination rates, several interventions, including outreach 
calls, an HPV Tool Kit, and an HPV workflow, were developed and implemented in 17 different 
pediatric clinics throughout the organization. As a result of the HPV Vaccination Improvement 
Project, the Burlingame pediatric clinic was able to increase the rates of HPV vaccination to 
meet and surpass the organization’s goals the following year. In 2017, there were 534 pediatric 
patients eligible to start the series; 166 of those patients completed the vaccination series, 155 
patients started, but did not complete the series, and 213 patients did not start the series. This led 
to a completion rate of 31.1%, which met and surpassed the 2017 completion rate goal of 30.4%.   
The most recent data is from April 2018, which shows that there were 545 eligible 
patients this year; so far only 92 patients have completed the series, 138 patients have started, but 
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not yet completed the series, and 315 patients have not started the series. The completion rate 
goal for 2018 has increased to 34.4%, however, as of April 2018 the actual completion rate was 
16.9%, almost halfway to the annual completion goal. Although it is important to acknowledge 
the efforts and the improvement that has already been accomplished by the Pediatric Service 
Line’s HPV Vaccination Improvement Project, it is also important to recognize that there is 
much more progress to be made to increase the rates of HPV vaccination to meet the 
recommendations of national experts, such as those established by Healthy People 2020. 
Although the initial HPV Vaccination Improvement project was able to increase the rates of 
HPV vaccination enough to meet and surpass the organization’s goal, it seems that the initial 
progress has not been sustainable.  
The Office of Disease Prevention and Health Promotion’s (OFPHP) (2018) Healthy 
People 2020, Objective IID-11 addresses the importance of increasing routine vaccination 
coverage levels for adolescents. More specifically, objectives IID-11.4 and IID-11.5 suggest 
increasing the coverage level of the HPV series for both females and males within the ages of 13 
to 15 years. In 2012, 28.1% of females, and only 6.9% of males, aged 13-15 years old, had 
completed the recommended HPV vaccine series (OFPHP, 2018). However, the target 
percentage, as proposed by Healthy People 2020, has been 80% for both males and females since 
2010. Although the objectives for Healthy People 2020 were written before the dose change in 
2016, it is clear that the clinic’s target completion rate for the HPV series should be much higher 
than what is has been. It is important for the clinic’s completion rate goal (and actual completion 
rate) to be more closely aligned with the Healthy People 2020 target of 80%, so that we can 
ensure that more of our patients can benefit from primary prevention through vaccination.  
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The Burlingame pediatric primary care office’s HPV vaccination initiation and 
completion rates are not only below the target rates of national recommendations, but they also 
remain below actual national and state rates. It is important to note that most national- and state-
level HPV vaccination surveillance data is limited to adolescents between 13- and 17-year-olds; 
however, we will use this information for comparison.  In 2016, 43.4% of adolescents (49.4% of 
females and 37.5% of males) had completed the HPV series (when the updated HPV 
recommendations were applied retrospectively) (Walker et al., 2017). Additionally, HPV vaccine 
initiation rates (adolescents vaccinated with at least one dose or more of HPV) varied from 
50.4% in rural areas, up to 65.9% in metropolitan areas (Walker et al., 2017). In 2012, 65.0% of 
adolescent females (13-17 years old) in California initiated the HPV vaccine series and 35.8% 
completed the series (Cook et al., 2014). In the same year, 29.4% of adolescent males of the 
same age initiated the HPV vaccine series and 11.7% completed the series (Cook et al., 2014). 
Increasing the rates of HPV vaccination series initiation and completion among the 
adolescent patients of the Burlingame pediatric primary care clinic is important because the HPV 
vaccine is most effective when given at a younger age, before the initiation of sexual activity and 
potential exposure to HPV (CDC, 2018).  
Available Knowledge 
 There has been a substantial amount of research on the barriers and facilitators to HPV 
vaccine uptake, as well as on specific interventions and strategies to improve the rates of 
adolescent vaccines, including the HPV vaccine series initiation and completion, among eligible 
patients. For this literature review, it is important to focus on past studies that focused on similar 
interventions as the ones proposed for this small test of change project (See Appendix A for 
evaluation table).  
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A population, intervention, comparison and outcome (PICO) question was developed to 
conduct a literature review to support the project: Can the implementation of outreach 
calls/reminders for adolescent patients who have not initiated or completed the HPV vaccine 
series increase/improve HPV vaccination rates compared to standard of care (no treatment)? The 
PICO question was used to conduct an electronic search in the Cochrane Database of Systematic 
Reviews, Pub Med, and CINAHL Complete databases. The most appropriate and useful finding 
was a systematic review from the Cochrane Library on patient reminder and recall interventions 
to improve immunization rates (Jacobson Vann, Jacobson, Coyne-Beasley, Asafu-Adjei, & 
Szilagyim, 2018).  The systematic review included a total of 75 studies, which included child, 
adolescent, and adult patients within outpatient, community-based, primary care, and other 
settings in 10 different countries. Due to the limitations of this project and time, it was not 
possible to review every study included in the systematic review. Twelve studies examined the 
effect of patient reminder or recall on receipt of adolescent immunizations; of these, only six 
were applicable to the intended project and will be further discussed in this section. Another, 
fourteen studies examined the effect of immunization reminder telephone calls (person-to-
person) on receipt of immunizations; only three of these studies could be applied to the intended 
project, but they were not included in the literature review because they did not add any new or 
useful information. The selected articles were evaluated using the Johns Hopkins Evidence-
Based Practice (JHEBP) research evidence appraisal tool (See Appendix B).  
 Brigham, Woods, Steltz, Sandora, and Blood (2015) conducted a randomized control trial 
(RCT) to determine if adolescent vaccination rates could be improved by contacting parents only 
or both parents and patients. The RCT included three study arms: in the control group (control), 
no specific outreach was initiated; in the first intervention arm (parent only), the parent or 
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guardian was called to inform of overdue vaccination; in the second intervention arm 
(parent/adol), both the parent/guardian and the patient were called to inform of overdue 
vaccination. Participants were identified from the Adolescent Medicine Practice at Boston’s 
Children’s Hospital by searching the EHR for patients with a billing code for a physical exam 
within the last three years; and included adolescents between 13- and 17-years-old that met the 
following criteria: those who had not received meningococcal vaccine (MCV4), had not received 
Tdap in five years, or had only received one varicella vaccine and did not have a history of 
varicella disease or chicken pox. Out of a total of 1099 individuals, 424 met the inclusion 
criteria. Subjects were followed for a year after the interventions; their immunization records 
were reviewed for any new vaccines at four weeks and one year after randomization (Brigham, 
Woods, Steltz, Sandora, & Blood, 2015).  
Brigham et al.’s (2015) study found that at four weeks after the intervention, there was a 
nonsignificant trend of increased immunization rates in both intervention arms (14.4% in parent 
only, and 14.5% in parent/adol), when compared to the control group (7.1%). The study found 
that the trend of increased immunization did not persist one year after the intervention (35.5% in 
the control, 41.4% in parent only, and 38.4% in parent/adol). Although the intervention showed 
improvement in vaccination in the short term, it was not able to sustain that improvement in the 
long term (Brigham et al., 2015). Although the study did not include the HPV vaccine as an 
adolescent vaccine, the findings on the efficacy of the intervention (telephone calls) can still be 
applied to the project. The evidence presented was a Level I and good quality (See Appendix A).  
Chao, Preciado, Slezak, and Lanfang (2014) conducted a randomized intervention study 
to determine if quarterly reminder letters would improve HPV series completion rates among 9- 
to 26-year-old females. Eighty percent of eligible females at Kaiser Permanente Southern 
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California (KPSC) who met the eligibility criteria were randomly selected to be in the 
intervention group. The intervention group received a letter reminding patients of the HPV 
vaccination schedule, the date of their first dose of HPV, a message to encourage the patient to 
return to the clinic to complete the series, and the phone number to call to schedule an 
appointment to receive vaccination. Three months after the first mailing, HPV vaccination status 
was re-evaluated for each participant; if they had not completed the HPV series, and did not meet 
any exclusion criteria, then they were sent another letter (four letters total). The rest of the 20% 
of eligible females were randomly assigned to the control group, which received standard of care 
and were not mailed any reminder letters.  
Chao et al.’s (2014) study found that the (3-dose) completion rate was 56.4% at the end 
of 12 months for intervention group, compared to 46.6% in the control group (p< .01). Patients 
who had only received one dose of HPV at baseline, 40% of those in the intervention group and 
30% of those in the control group were able to complete the HPV series. In contrast, in the same 
group, 20% of girls (9-17-years old) and 43% of young women (18-26-years old), did not receive 
any additional doses of HPV during the 12-month-long intervention period. This study is 
relevant to the project because we will be sending mailed reminders or outreach letters for those 
patients that we are not able to contact by phone, so it is important to examine the validity of this 
intervention as well. The evidence presented was Level I and good quality (See Appendix A). 
 Suh et al. (2012) conducted a RCT to determine if a combination of reminder/recall (R/R) 
intervention, including auto dialer telephone calls, followed up by a letter reminder, would 
increase the receipt of one or more targeted vaccines, as well as receipt of all targeted vaccines 
within six months of the intervention, compared to a control group treated with usual care. The 
study involved 400 patients, from four private pediatric practices, for a total of 1600 participants. 
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Patients were 11- to 18-years-old, who had been seen within the last two years and who had not 
received one or more of the following vaccines: Tdap, MCV4, or first HPV for female patients 
only. A secondary outcome of the study was to determine the completion of the following 
vaccine series at 12 months after the intervention: Hepatitis A and B, Varicella, and HPV for 
females only.  
 Suh et al. (2012) found that a significantly higher percentage of patients in the 
intervention group received at least one of the targeted vaccines (p<.001) and there was also a 
significantly higher percentage of patients in the intervention group that received all targeted 
vaccines (p<.001). Overall, there was a significant increase in the intervention group for each 
vaccine, but HPV rates still remained lower than the other two targeted vaccines (Tdap and 
MCV4). This study also considered the cost of the intervention to improve vaccination rates, and 
they completed a cost analysis for the project. The cost analysis showed a positive net revenue 
and positive net additional revenue for three of the four practices, although one practice showed 
a loss (Suh et al., 2012). This study is relevant to the project because we will be utilizing a 
similar combination of outreach methods. The cost benefit analysis is also useful to support the 
cost effectiveness of these types of interventions. The evidence presented was Level I and high 
quality (See Appendix A).  
 In another study by Szilagyi et al. (2006), a RCT was conducted to compare the effect of 
audiotaped telephone reminders for scheduled or needed immunizations and physical exams with 
standard care. The study identified 5,902 adolescents between the ages of 11- and 14-years-old, 
however only 3,006 were eligible for randomization. Patients had to have been seen within the 
last two years and be due for an annual physical, tetanus booster (Td), or Hepatitis B vaccination. 
Participants in the study group were called weekly if there was no response. Szilagyi et al. (2006) 
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found that at the end of the study, the intervention group had higher coverage of Hep B when 
compared to the control group (62.0% and 57.8%). Although both groups increased rates of Hep 
B and Td vaccinations, only the increase in Hep B vaccination was significant. The intervention 
was most effective at the beginning of the study, but the positive effects were not persistent. 
Although the study is older, and was conducted before the HPV vaccine was approved and 
recommended for adolescents, the findings can be useful and applied to other adolescent 
vaccines. The study is relevant because the intended project has a short duration, and based on 
these findings should lead to improved vaccination rates in the short term. The evidence 
presented was Level I and good quality.  
 Szilagyi et al. (2011) conducted another RCT to determine if this time a tiered 
intervention provided by a trained patient immunization navigator to improve adolescent 
vaccination rates was more effective than the previous study. Patients were selected from eight 
different primary care practices in Rochester. Patients had to be between 11- to 15-years old and 
had to have been seen in the office within the last two years; 7,547 adolescents were identified 
and randomized into two different groups. The intervention group involved different levels of 
outreach, with each subsequent level being more intensive than the last. Patients in the 
intervention group were tracked, and then were sent telephone and mailed reminders/recall. If 
patients did not respond to those efforts, home visits were made to determine and assess any 
other barriers to vaccination. Because home visits took more time and were costlier, this 
intervention was only used sparingly. The control group received standard of care; however, all 
practices were already sending letter and telephone reminders for scheduled visits, but there were 
no active reminders or recall based on vaccination status (Szilagyi et al., 2011).  
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 The study by Szilagyi et al. (2011) found that immunization rates increased by 12 to 16% 
for all three adolescent vaccines (including HPV in females) in the intervention group compared 
to the control group. Preventive care visit rates were also higher in the intervention group by 9-
17%. This study was relevant because the intervention was carried out by a trained patient 
immunization navigator, as opposed to someone who might not be knowledgeable regarding the 
clinical aspects of vaccinations. The evidence presented was Level I and great quality (See 
Appendix A).  
 The final study is another by Szilagyi et al. (2013), where a RCT was conducted to 
determine which intervention (mailed reminders or telephone calls) was more effective to 
increase vaccination rates compared to standard of care control group. Patients had to not have 
had a preventive care visit within the last 14 months and/or be eligible for Tdap, MCV4, or HPV 
vaccine; 4,115 patients were selected among 37 primary care offices. Adolescents were 
randomized into one of three groups. In the first intervention group, letters were mailed every 10 
weeks (max of five reminders in one year), except for HPV where letters were mailed every 10 
weeks for the first dose only, and every 5 weeks for the second or third dose of HPV (max of 
eight reminders per HPV dose). In the other intervention group, telephone calls were made at the 
same frequency that the letters that were sent. The control group received standard care from 
each practice; however, some practices already used some sort of telephone or mailed reminders 
for scheduled visits and for patients behind on vaccinations (Szilagyi et al., 2013).  
 The study found that immunization rates for individual vaccines and rates for all vaccines 
combined were 4-9% greater in the intervention group compared to the control group (Szilagyi et 
al., 2013). There was not much difference in improvement rates between the two interventions, 
but the difference between the intervention groups was significant when compared to the control 
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group. There were also fewer missed opportunities for vaccination in the intervention groups 
compared to the control group. About 13% of patients in the control group received all 
vaccinations, but preventative visits actually declined in the control group from 63 to 59% 
(Szilagyi et al., 2013). The study is relevant because it supports the proposed intervention, and 
the sample size was from many different types of care settings, thus the results can be 
generalizable to other practices. The evidence presented in this study was Level I and great 
quality (See Appendix A).   
 A common theme throughout the literature review is the frequency with which 
reminder/recall interventions are recommended and encouraged as an effective strategy to 
improve vaccination rates among various populations, and experts, such as the Task Force on 
Community Preventive Services, have recommended this strategy (Szilagyi et al., 2013). 
However, the evidence available to support this intervention has been mixed between negative 
and positive outcomes. Many of the studies included in the literature review suggest that 
reminder/recall interventions do provide at least some positive effect on vaccination rates 
compared to control groups, however, the benefits of this strategy are often limited to the short 
term and often blunted due to a lack of accurate contact information (telephone number or 
mailing address) for patients.  
Rationale 
 Increasing HPV vaccine rates in our pre-adolescent and adolescent patients has already 
been a priority for the primary care clinic for more than two years. Although we have already 
seen some improvement in the rates and were able to meet the organization’s goals, our HPV 
immunization rates still remain below the national targets. However, it is important to take 
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advantage of the current momentum and recent victories, to encourage and support the quality 
improvement efforts even further.  
Although the HPV Vaccination Improvement Project already attempted to use outreach 
calls as an intervention or strategy to improve HPV vaccine uptake, the microsystem assessment 
revealed that the last of the outreach calls were done sometime last year. Additionally, the 
outreach calls that were done before, were done by a group of patient service representatives 
(PSRs) outside of the clinical area. The PSRs were also responsible for making outreach calls to 
all of the 17 pediatric clinics, which is a very large undertaking. However, it is unclear whether 
the PSRs had any previous training or education with pediatric patients, vaccination schedules 
and recommendations. In the study done by Szilagyi et al. (2011), the intervention was carried 
out by a trained patient immunization navigator and the results of the intervention were positive. 
Although the authors did not make a correlation between the results of the study and the training 
or education of the immunization navigator, it would be interesting to investigate if outreach 
calls done by clinical (and knowledgeable) pediatric staff will improve the results of the 
intervention; this is assuming that the clinical staff would be able to answer any questions and 
provide rationales for the HPV vaccine.   
Initial inspiration for this project was based on the “4 Pillars of Practice Transformation 
Program” (4 Pillars Program), which was found during a previous literature review (Zimmerman 
et al., 2017). The 4 Pillars Program is an evidence-based, step-by-step guide used to improve 
immunization rates in outpatient settings (University of Pittsburg, 2018). Zimmerman et al. 
(2017) conducted a pre-post study using Diffusion of Innovations theory, the 4 Pillars Program, 
provider education, and individual coaching of an Immunization Champion for each clinical site. 
Each practice was expected to choose and implement strategies from each of the four pillars; 
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they were also encouraged to employ as many strategies as possible in an attempt to maximize 
effects of the program on vaccination rates. Strategies used by the different practices included: 
using every opportunity to vaccinate, developing and implementing standing order protocols for 
RNs to vaccinate, reminding patients of subsequent doses, and office wide recommendations 
encouraging vaccinations (Zimmerman et al., 2017). Researchers found that primary care 
practices who implemented the 4 Pillars Program were able to observe clinically and statistically 
significant improvements in HPV vaccine series initiation and completion, as well as 
improvements in other adolescent vaccines, including: meningococcal and Tdap vaccines 
(Zimmerman et al, 2017).  
Although the initial plan was to use the 4 Pillars Program as a guide for the quality 
improvement project, due to the limitations and time constraints of the project, the plan was 
eventually simplified to focus on just one intervention/strategy to try to improve HPV vaccine 
series initiation and completion rates in the pediatric setting. We chose a reminder/recall 
intervention, which falls under Pillar 2: Patient Communication Strategies; however, this 
intervention is related to other interventions under different pillars (See Appendix C) (University 
of Pittsburg, 2018).  
Various theories have been used to introduce the 4 Pillars Program in the primary care 
setting (Zimmerman et al., 2018). However, since this quality improvement project will be led by 
the CNL student, who is in the perfect position to support and reinforce the quality improvement 
process, we will use and focus on Lippit’s phases of change theory (See Appendix D) as a guide 
and framework to implement the outreach call/reminder/recall intervention in the pediatric 
primary care clinic. Lippit’s theory is especially useful for the CNL because it focuses on the 
change agent and highlights his or her ability to work together with the interdisciplinary team to 
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improve patient outcomes through the application of evidence-based practice.  Lippit’s phases of 
change theory will be discussed further in the context section of this paper.  
Specific Project Aim 
The purpose of the quality improvement project is primarily to improve the initiation and 
completion rates of the HPV vaccine series in the pediatric clinic. As we review each patient’s 
electronic health record and immunization report, we expect to find other vaccines or 
preventative visits (annual physicals) that are overdue. In an attempt to improve primary 
prevention and reduce missed opportunities, a secondary purpose of the project is to ensure that 
patients are up to date with other routine and adolescent vaccines, as well as preventative visits.  
 Our global aim statement is as follows: We aim to improve the initiation and completion 
rates of HPV vaccination in the BG pediatric primary care clinic. The process begins by 
identifying patients who are eligible to initiate the HPV vaccine series but have not done so and 
patients who have initiated, but not yet completed, the HPV vaccine series. The process ends 
with scheduling patients to come in for a physical exam or a care team visit to accept/receive the 
HPV vaccine (and any other vaccines that may be overdue). By working on the process, we 
expect (1) to increase the HPV initiation and completion rates to meet and surpass the 
organizational goals, and (2) to reduce the gap between our completion rate and the national 
target rate of 80%(ODPHP, 2018). It is important to work on this now because we have 
identified the need to improve (1) our HPV vaccination initiation and completion rates to meet 
organizational goals and national targets, (2) there is no standardized process to track and reach 
out to patients who are behind on their HPV vaccines, and (3) to reduce missed opportunities to 
vaccinate. 
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 Our specific aim is as follows: We aim to improve the initiation and completion rate of 
the HPV vaccine series in the BG pediatric primary care clinic, through outreach calls and 
mailed letter reminders of overdue vaccines or physical exams starting July 9th, 2018. We hope to 
improve HPV vaccination rates and completion by 5-10% within three weeks, by July 30th, 2018.  
Context 
As previously discussed, the BG pediatric primary care clinic has already participated in 
a previous (and still current) quality improvement project to increase HPV immunization rates 
among adolescents who are 11- to 13-years-old. Previous strategies and interventions have been 
shown to be effective enough to increase the HPV immunization rates to meet the organizational 
goals, but not national targets. It is important for the CNL to take advantage of the momentum 
and organizational support that already exists regarding this topic, to promote buy-in and staff 
interest and collaboration for the new project. Additionally, success of previous quality 
improvement efforts supports a culture of safety within the microsystem, as well as reflects the 
staff’s commitment to improving patient care.  
Cause and Effect: Fishbone Diagram  
 As part of the microsystem assessment the team created a fishbone diagram to illustrate 
possible causes for low HPV rates in the pediatric primary care clinic (See Appendix E). Some 
of the more common barriers to HPV vaccination appear to be related to the patient (and their 
parents or guardians). These reasons demonstrate that there is need for more education regarding 
the HPV vaccine and vaccine-preventable diseases. Outreach calls that are done by clinical staff 
can be useful to provide some of this education to our families as well as clarify any 
misunderstandings that they may have that have prevented the patient from receiving the HPV 
vaccine in the past.  
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 Process issues also seem to point to problems scheduling appointments through the call 
center. Part of the problem relays back to the issue of education and knowledge of the HPV 
vaccine; where the PSR may not be familiar with the HPV vaccine and the recommended 
schedules. We have found that many PSRs schedule appointments based on the patient snapshot, 
which is sometimes inaccurate, outdated, or does not reflect that the patient is on an alternative 
vaccination schedule. Outreach calls by trained and knowledgeable clinical staff would bypass 
the need for the parent to navigate through the call center telephone tree, as well as provide more 
accurate and patient-centered guidelines for vaccines. Additionally, clinical staff who are local to 
the clinic are able to manipulate the NonMD schedule to fit the needs of the patients by 
collaborating with providers and other care team members to offer appointments that the PSRs in 
the call center may not have access to due to provider blocks.  
SWOT Analysis 
 It was also important to create a SWOT Analysis as part of the microsystem assessment 
to discuss the strengths, weaknesses, opportunities and threats for the quality improvement 
project (See Appendix F). One of the main findings of the SWOT analysis (which is also 
reflected in the cause and effect diagram) is the increased rate of recent staff turnover and 
inadequate staffing. Although this is very common and pervasive problem in healthcare, staff 
turnover has been unusually high in the BG pediatric primary care clinic to the point where it is 
now at a 100% of supportive and direct patient care staff, including medical assistants (MAs) and 
LVNs. Consequently, we have had various different float staff from the float pool covering the 
clinic and the Non MD schedule, as well as staff from other pediatric clinics floating to the BG 
location.  
 This issue has created many different problems in the clinic, internally and externally. It   
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also affects the ability of the CNL to implement a quality improvement project without a 
dedicated and consistent staff. Additionally, this issue creates more of a task-oriented staff and 
focus, such as a “let’s just get things done” or “let’s just get through the day” type of an attitude 
that does not support quality improvement efforts. One way to address this issue, is to create a 
“cheat sheet” for the floating staff in regards to common HPV questions, so that new staff is 
prepared to answer vaccine questions in a consistent manner. Since there was already a pre-
existing resource created by the initial HPV Vaccine Improvement project, it was not necessary 
to recreate this document again (See Appendix G). Additionally, communication between the 
care team (CNL/RN, MA, LVN, MD) becomes even more important and critical for efficient 
patient care. 
Return on Investment (Cost Analysis) 
 As with any quality improvement project, it is important to address the economic side of 
an intervention and small test of change. The team met to develop and create a business case for 
the project because a thorough cost-benefit analysis is important to stakeholders within the 
organization. Additionally, the increasing importance of fiscal stewardship within healthcare 
affects the stakeholders, as well as the microsystem staff; it would be irresponsible for the staff 
to take on a project without being aware of the potential cost and benefit to the organization. 	
Costs. Expected costs would include the salary rate of the CNL to develop and 
implement the project. According to NurseJournal.org (2018), the national median annual wage 
for a CNL is $84,000 or about $40.38/hour (assuming a 40-hour work week). For a project that is 
expected to take about 220 hours, this would mean a total cost of $8,883.60. The proposed 
intervention of outreach calls should not incur extra costs other than time, since we have the 
equipment and services in the clinic already (telephone, telephone service). We have access to 
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patient demographics (telephone number and address) via the EHR that is already in place, as 
well as the ability to send messages through the EHR. Cost of the project may be reduced if other 
staff can be recruited to help with outreach calls. According to Salary.com (2018b, 2018a), the 
median expected hourly pay for a medical assistant in the US is $16, and the median annual 
salary for a clinic receptionist is $34,106 or $16.40/hour; which would reduce the cost for the 
project down to about $3520 - $3608.  
Other costs to consider would be the cost of the vaccines; if we are able to increase the 
rates of HPV vaccination then we would need to order more vaccines and supplies to 
accommodate increased demand. According to the CDC (2018), Guardasil-9 (which is the 
vaccine we use at the BG clinic) costs $204.87 per dose for private sector; we do not have any 
vaccines provided by the Vaccines for Children (VFC) Program. Guardasil-9 comes in a box of 
10, translating to a cost of $2,048.70 per box. Since the goal of the project is to increase HPV 
initiation and completion rates by 5-10%, this would translate to an additional 28-55 HPV 
vaccines, or an additional cost of $5,736.36 - $11,267.85.  
Benefits. Benefits to the employer would include the reimbursement for the service of 
providing vaccines. According to Sutter (2015) Healthcare Cost Estimator, Human 
Papillomavirus (HPV) vaccine, 3 dose total charge is $260, with total patient responsibility being 
$234 (for uninsured patients). Additionally, there is an immunization administration with face to 
face counseling cost of $65, with total patient responsibility of $45. The total billed charge is 
$325, and total patient responsibility is $279. This would translate to a benefit of $7,812 - 
$15,345. A doctor’s office visit for an established patient, nurse visit is charged at $63 and 
patient responsibility is $57. A doctor’s office visit for an established patient, moderate level 
visit is charged at $220 and patient responsibility is $198. This would mean an additional benefit 
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of $1,596 - $3,135 for nurses visits, or $5,544 - $10,890 for physical exam, where patients would 
be able to receive vaccines in either type of visit.  
Net Benefits. The goal of the project is to increase HPV immunization by 5-10% or 28-
55 patients. The different variables (how many vaccines are needed for completion per patient 
and type of visit appropriate for each patient) make it a little difficult to determine the net 
benefits. However, a rough estimate will be based on just one vaccine given per patient during 
the project duration. For simplicity purposes and to estimate the lowest (most conservative) net 
benefits, this will be calculated using nurse visits as the type of visit for patients to receive 
vaccines. Based on these parameters, for each patient, benefits would equal to $336 ($279 + 
$57); for a 5-10% increase, benefits would equal $9,408 - $18,480. The net benefit would be 
~$524.40 - $9,596.40.  
Qualitative Benefits. Qualitative benefits to the patient would include reduced risk of 
infection with HPV (and its’ associated cancers) and overall improvement of quality of life. This 
would translate to a reduction in the direct and indirect medical costs of the disease and its’ 
treatment.  
Qualitative benefits to the clinic (the employer) would include improvement of HPV 
vaccine initiation and completion rates, putting the clinic (and organization) more closely aligned 
with national recommendations and targets. Additionally, reduced missed opportunities for 
vaccination translate to improved efficiency and patient satisfaction, and reduces the need for 
additional visits. Earlier (younger) HPV vaccine series initiation and completion reduces the 
amount of vaccines needed to complete the series-- which can be more cost effective for the both 
the clinic and the patient. 
Lippitt’s phases of change theory revisited 
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 Lippitt’s phases of change theory was introduced in a previous section, but it is important 
to discuss it here as well. Although there are many different change theories available to guide a 
change process, it is the responsibility of the change agent to select the most appropriate theory 
for the project after considering the culture of the microsystem. Although Lippit’s (1958) theory 
is more complicated than Roger’s Diffusion of Innovations theory, it provides the change agent 
with a more detailed plan of how to realize change successfully (as cited in Mitchell, 2013). 
Furthermore, since Lippit’s theory is based on the four elements of the nursing process, the 
process is familiar to all nurses, including the CNL, and provides a good starting point for novice 
change agents and clinical leaders (Mitchell, 2013).  
Lippit’s theory is applicable to the microsystem now because it focuses on the change 
agent, rather than the change itself. It is important that the change agent focus on effective 
“communication, feedback on progress, teamwork and motivation” (Mitchell, 2013, p. 36). Since 
the clinic is going through a major change in staff, it is especially important for the CNL to take 
on the leadership role of the quality improvement project and guide the float staff through the 
process. Although teamwork and collaboration is still an important part of the project, the CNL 
must be creative and innovative in order to motivate the staff to commit to and participate in the 
quality improvement project, especially when they have competing priorities.  
In the final stage of Lippitt’s theory, it is important for the change agent to take a step 
back at the end of the project, and let the team embrace and integrate the change into the 
microsystem; however, it is helpful for the change agent to still be available for support to and 
encouragement for the team (Mitchell, 2013). We are hopeful that by the end of the project, we 
will have better and more consistent, possibly permanent, staffing of the clinic. At that point it 
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will be easier for the CNL to step back and allow the team to embrace and be responsible for a 
larger portion of the project, if we determine that it is successful.  
Intervention 
 Through a microsystem assessment and discussion with our pediatric PSR, it was 
discovered that there is already a list of patients who are overdue to initiate or to complete the 
HPV vaccination series. This report is left over from when the HPV Vaccination Improvement 
Project was doing outreach calls last year. The status of this report, and whether it has been 
updated and maintained, is unknown. However, since the HPV Vaccination Improvement Project 
team is still generating reports to update the HPV initiation and completion rates of each clinic, it 
is possible that the list still exists. We have contacted one of the Pediatric Service Line’s 
coordinators to request a copy of this list and are waiting to hear back.  
If it is possible to obtain the list, then we will initiate outreach calls based on the patients 
on the list who belong to the BG pediatric primary care location. Depending on the amount of 
patients on the list, we will attempt to make at least one initial call per eligible patient to remind 
them that they are due for an HPV (and any other) vaccination and offer to schedule them for a 
care team visit (nurses only) or a physical exam, depending on which visit is most appropriate. 
Prior to initiating the call, we will review each patient’s immunization report, check their last 
appointment visit, check their last physical exam, and check for any scheduled or upcoming 
appointments. We will use demographic information (telephone numbers) that are already 
entered in the patient’s electronic record. Although some studies in the literature review 
attempted to call and remind the patient directly, our project will only reach out to the 
parent/guardian listed on the patient’s chart.  
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If we are not able to obtain a copy of the list of eligible patients for the HPV vaccine, 
then we will have to look for them manually on EPIC, the electronic health record. We will 
search for patients based on their birthdates, starting with those born between and 7/9/2005 and 
7/9/2007. This search should retrieve patients who are between 11- and 13-years-old, which has 
been the target population of previous HPV improvement efforts. After the initial search based 
on birthdate, we should be able to create a list of patients who belong to the BG primary care 
clinic, based on the primary care provider listed on their chart. This method would be a last 
resort, but would still be effective if needed.  
If a parent declines to schedule for an HPV (or other) vaccine, the patient will be placed 
on a list for follow up, but will no longer receive calls. If a parent does not answer, we will leave 
a scripted message on their voice mail if possible. If a parent does not answer, and we are not 
able to leave a message, we will attempt to call the parent again on another day. If we do not 
have an updated phone number for the patient (the phone number is not active or we are 
informed we have the incorrect phone number), we will follow up with a letter sent to the 
address on file. If a parent answers and agrees to schedule a visit, an appointment will be secured 
at that time and a future order for necessary vaccines will either be pended to the RN by the 
medical assistant, or ordered and signed by the RN. If a PSR secures the appointment, they will 
send a request for orders for the vaccines to the care team.  
Measures 
According to a video from the Institute for Healthcare Improvement (IHI) (2018), which 
discusses the family of measures, the two most important measures are outcome and process 
measures. Outcome measures reflect the impact of the health care intervention or strategy on the 
health status of patients (Agency for Healthcare Research and Quality, 2015). For this project, 
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outcome measures would include the HPV vaccination initiation and completion rates, and 
number of HPV vaccines given per day, week, and duration of the project. Process measures are 
what a healthcare provider does to maintain or improve health (AHRQ, 2015). For this project, 
process measures would include the number of phone calls made, number of letters sent, and 
number of appointments scheduled as a result of the outreach and reminder/recall efforts.  
According to the “4 Pillars Program”, it can be useful to track the “used opportunities to 
vaccinate”, which can be calculated by dividing the number of people vaccinated by the number 
of persons seen (University of Pittsburg, 2018). Additionally, the number of “simultaneous 
immunizations” given can also be useful, and that is calculated by the number of persons given 
two or more vaccines during the same visit divided by the number of persons given at least one 
vaccine (University of Pittsburg, 2018). Both of these would examples of an outcome measure, 
but they could also be seen as balancing measures (See Appendix I).    
Ethical Considerations 
Two of the major ethical considerations of this project include patient privacy and 
autonomy. The HPV vaccine is one of the few vaccines that does not require parental consent for 
it to be administered to a patient under the age of 18. In 2011, California law AB 499 or Chapter 
652 gave minors, 12- to 17-years-old, the authority to consent to medical services that provide 
prevention of sexually transmitted diseases (Hepatitis B, HPV, and HIV) without their parent’s 
consent (California Immunization Coalition, 2013). If a patient is in the clinic and requests an 
HPV vaccine without their parent’s consent, we do our best to maintain our patient’s privacy and 
accommodate their request. Similarly, if a patient calls to make an appointment for an HPV 
vaccine and wishes to keep it private from their parent’s, we will work with the patient to protect 
their privacy and respect their right to make the choice for themselves.  
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These issues become a little more complicated and can be tricky when calling parents to 
remind them about their child’s overdue HPV vaccinations. For example, if a patient received 
their first HPV vaccine without the knowledge or consent of the parent, and we call the parent to 
remind them that the patient is due for their second dose, this could create a potential breach of 
patient privacy, as well as conflict between the parent and the clinic or the parent and the patient. 
We were unable to find any recommendations in the literature review to mitigate these 
confidentiality issues, which was surprising because it would be expected for similar issues to 
arise in other clinics and with other improvement projects. However, one of our lead physicians 
suggested looking up the previous consent for the HPV vaccine (which is usually available and 
scanned into the patient’s chart) to confirm who signed for the last vaccine consent.   
Results 
The pediatric primary care clinic started planning for the project on May 21, 2018, 
however, implementation of the first PDSA cycle of the project was expected to start July 9, 
2018. Due to a delay in access to the eligible patient list, we were unable to start the outreach 
calls until July 13, 2018. The first PDSA cycle of the project was expected to run for three 
weeks, finalizing by July 30, 2018; however, the last day of outreach calls was July 27, 2018. 
Final data measurement for this PDSA cycle was also to be completed by July 30, 2018. Please 
refer to timeline for more detailed explanation of the project’s progress (See Appendix I) and 
PDSA cycle for more information (See Appendix Q). 
According to the most recent data report, there were 545 eligible patients in April of 
2018. Our initial plan was to call all of these patients at least once. However, we did not expect 
that the outreach calls would take as long as they did. Some calls took between 5-10 minutes, 
which included a chart review to check on their HPV status, and if they were due for any other 
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vaccines or physical exam. Also, for every patient that had already initiated the HPV series, we 
had to check if the prior consent had been signed by the parent or the patient to avoid a breach in 
patient confidentiality. On the other hand, some calls took as long as 25-30 minutes, because 
parents wanted us to check to see if their other children were due for vaccines or a physical exam 
as well. Although the additional time spent helping parents with non-HPV appointments did not 
benefit the project, it did benefit our overall patient care and improved access. Unfortunately, we 
were only able to make 78 patient calls, which translates to 14% of our initial outreach goal.   
Initially we also planned to follow up patient calls with mailed letters or electronic 
messages through the patient portal. However, because the outreach calls were so time 
consuming we were unable to send out any letters or messages. At the end of the project, we 
decided that this would be a good strategy for a second PDSA cycle if the project was allowed to 
continue. There were some initial concerns for patient privacy regarding mailed reminder letters, 
consequently it would be important to have a team meeting to discuss and mitigate these 
potential issues if we did move forward to the next PDSA cycle.  
During the project we tracked a lot of different measures and outcomes. Some of the data 
was obtained through chart reviews, which were also more time consuming than expected. The 
rest of the data was obtained by keeping a log of patient calls and the outcomes of those calls 
(See Appendix J). The data gathering process would have been more time- and cost-effective if 
there was a way to automate the process through a report of some kind. Although we discussed 
the possibility of connecting with an EHR specialist to help the process, we were unable to do so 
during the time of project implementation. However, if the project is expected to continue, doing 
so would streamline the process and make it much easier to keep track of some of the measures. 
Additionally, learning how to run these reports and having access to them would free up more 
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time for outreach calls and would enable the team to reach out to more patients, increasing the 
benefits of the project.  
One of the main outcomes that we tracked was the “number of HPV vaccines given” (See 
Appendix K). There seem to be less points below the median after the HPV outreach calls were 
implemented, but it is hard to tell because there is not as much data as in the baseline. We 
tracked “missed opportunities for vaccination” (See Appendix L). After project implementation 
the points above the median are not as high, and more points seem lower than during the baseline 
data; suggesting a decrease in this measure. However, it is possible that this measure decreased 
simply because it is “back to school season”, where there is an increased number of patients 
being seen for physicals and school-mandated vaccines, instead of the benefit being related to the 
efforts of the quality improvement project. We thought it would be interesting to track “missed 
opportunities for vaccination” specifically to HPV since this was the main focus of the project 
(See Appendix M). Again, there seem to be more points below the median after project 
implementation, except for the two high points towards the end of the data. One possible 
explanation for the increase in missed opportunities for HPV could be related to the new 
adolescent vaccine workflow that I described previously; mainly the first HPV now being 
recommended at 10 years old. Conversely, it could also be related to the office seeing more 
patients for physicals and families requesting to have only vaccines that necessary for school 
registration and entry. “Used opportunities to vaccinate” (See Appendix N) and “simultaneous 
vaccines given” (See Appendix O) were also tracked as balancing measures. Although there was 
no increase in either measure as a result of the project, there does seem to be less points below 
the median baseline in both data sets.  
Summary 
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    As a result of the project, we attempted to call 78 patients and we were able to reach 69 
patients total. We were unable to reach nine of those patients due to them moving, switching 
providers, or not having updated contact number on their patient information section of the chart. 
Out of the 69 patients reached, we left 37 messages and scheduled 25 initial appointments for 
either a physical exam or a nurse-only (injection-only) visit. Three patients outright refused the 
HPV vaccine and four patients gave an excuse to avoid scheduling an appointment during the 
outreach call. A second review of the data was completed about two weeks after the end of the 
outreach calls, and we discovered that an additional 15 appointments were scheduled as a result 
of the messages that were left, for a total of 40 appointments scheduled. Out of the patients who 
came in for their appointments, 11 patients completed the HPV series and two patients initiated 
the HPV series; this led to an improvement of about 2%, which was less than our goal of 5-10% 
improvement. However, because of the appointments scheduled were future appointments, we 
were unable to collect a significant portion of the data. If all 40 patients who were scheduled as a 
result of the outreach calls came in to their appointments and received an HPV vaccine, then that 
would translate to an improvement rate of 7% which would meet our goal.  
    We suspect that the “back to school” season was helpful to increase the amount of patients 
who were willing to come in for a visit. About half of the patients scheduled were also due for a 
physical exam and this seemed to help motivate the families to come in because they also needed 
to have school forms filled out by the physician. Interestingly, a review of the appointment data 
illustrates that the appointment types were evenly split in half, 20 patients were scheduled for a 
physical exam, and 20 patients were scheduled for a nurses visit.  
Conclusion 
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Based on our results of this short test of change, we concluded that outreach calls were 
helpful to improve the HPV initiation and completion rates at the BG clinic. Although the initial 
improvement rates did not meet our improvement goal, there is definitely potential for the 
strategy if it is adopted on a more long-term basis. Our findings were somewhat consistent with 
the results of the literature review, since we did experience some improvement in our HPV rates. 
The literature review did warn that the benefits of outreach calls are not sustainable, however it 
is hard to say if this is true for our clinic. It would be important to test this strategy for a longer 
and more consistent basis to determine whether this is accurate. On the other hand, it would be 
important to make some changes to the process of the outreach calls to ensure that it is 
sustainable.  
Initially, we thought that a clinical person, such as the CNL, would be in the perfect 
position to execute the outreach calls due to their increased knowledge of the HPV disease and 
vaccine. As a clinician and educator, the CNL is in the best position to address many of the 
common reasons for HPV vaccine refusal. However, during the process of the outreach calls, it 
became evident that most people were already decided one way or the other. Those who opposed 
the HPV vaccine, did so strongly and did not really want to discuss their decision. Those who 
agreed to the HPV vaccine were appreciative of the reminder calls and were willing to schedule 
an appointment; in this case, it was more a matter of convenience or access and availability. 
Consequently, in order to sustain this type of outreach it would be important to recruit other (less 
costly?) staff members in order for the project to be more cost-effective. Since now we also 
know that the outreach calls can take a long time to complete, it would be necessary to have 
dedicated time for this outreach that does not take time away from direct patient care and other 
day-to-day responsibilities.  
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As previously discussed, PSRs were already been doing outreach calls as part of the 
initial HPV Improvement Project that was started in 2017. This group of staff was in charge of 
outreach calls for 17 different pediatric clinics and did not have a knowledge or familiarity with 
the nuances of each clinic and patient population. The previous attempt at outreach calls were 
also not very consistent, and it was unclear when the outreach calls had stopped or if they were 
still ongoing. Therefore, if the BG clinic is able to embrace and sustain the project as part of the 
daily clinic responsibilities and we can show that the strategy is effective in increasing our HPV 
rates, we could then attempt to spread the project to the other three pediatric clinics in the 
division, and ultimately to the other 13 clinics in the organization.  
It is evident that there is still much work to be done in order to increase the rates of HPV 
vaccine initiation and completion to meet the recommendations and guidelines of national 
experts; this is true for our clinic as well as for other clinics across the state and across country. 
Outreach and reminder calls are just one strategy that has shown to be of benefit, however, it is 
important to consider and research other strategies as well. Thankfully, there is a significant 
amount of research and evidence-based recommendations to improve HPV and other vaccine 
uptake in the primary care setting. However, it is important for the clinic and staff to be proactive 
and search out this information to improve the outcomes of our patients by providing them with 
the best preventative care possible. As healthcare continues to move away from just treating 
illness and disease, and becomes more focused on prevention, preventative measures such as 
vaccines will become more even more important to track as they have been proven to increase a 
patient’s quality of life and improve their outcome in the long-term.  
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Appendix A 
Citation (APA) Type  Patients/ 
Subjects 
Interventions/ 
Comparisons 
Outcomes  Evaluation 
(strengths, 
weaknesses, 
relevance) 
Brigham, K. S, Woods, 
E. R., Steltz, S. K., 
Sandora, T. J., & Blood, 
E. A. (2015). 
Randomized controlled 
trial of an immunization 
recall intervention for 
adolescents. Pediatrics, 
130(3), 507-514. DOI: 
10.1542/peds.2012-0471 
 
RCT  -13-17 year 
olds at 
Adolescent 
Medicine 
Practice at 
Boston’s 
Children’s 
Hospital 
-overdue for at 
least 1 of 3 IZs 
(MCV4, Tdap, 
Varicella). 
-Recent 
physical within 
3 years   
-1099 patients 
identified, 424 
met inclusion 
criteria  
3 groups  
-Control group (no 
treatment) (1) 
-Telephone calls to 
the parent/guardian 
(Parent Only) (2) 
-Telephone calls to 
the parent/guardian 
and the adolescent 
(Parent/Adol) (3) 
-Intention to treat 
analysis: 
improved IZ rates at 4 
weeks for both 
intervention arms: 
1. 7.1% 
2. 14.4% 
3. 14.5% (P=.09) 
-unadjusted odds of 
receiving 1 or more 
vaccines during 4-week 
follow-up period were: 
2. 2.20 x higher (95% CI 
0.99-4.89)  
3. 2.22 x higher (95% CI 
1.00-4.94) 
-adjusted odds 
(stratification and 
demographic factors) 
2. nonsignificant OR 2.02, 
95% CI 0.89-4.56 
3. OR 2.27 95% CI 1.00-
5.18 
-As-Treated Analysis: 
2. 79 (56.4%) of 
parents/guardians were 
successfully reached 
3. 70 (50.7%) of the 
parents/guardians and 30 
(21.7%) adolescents were 
successfully reached 
-Post Hoc Analysis: 4 
weeks after actual 
intervention, showed: 
significant increased rate 
of IZ when 
2. 24.4% parent alone was 
reached 
3. 20.1% parent and 
adolescent both reached 
1. 5.6% with no contact 
-Multivariate analysis:  
2. OR 5.31 (95% CI 2.66-
10.63 
3. OR 4.72 (95% CI 1.62-
13.79) 
Other: 
Age was also an 
independent predictor of 
receiving an 
immunization, with older 
adolescents being less 
likely to receive an 
immunization 
-Post Hoc Analysis: 1 year 
after actual intervention 
showed: 
1. 30.0% no contact 
(P<.001) 
2. significant increased 
rate of IZ (51.3%) 
Strengths:  
-Showed improvement 
in vaccination rates in 
the short term 
- Shows the importance 
of clinics maintaining 
UTD contact 
information for 
patients/parents 
Weaknesses:  
-Did not show 
improvement over the 
long term 
-Difficult to reach 
parents/patients by 
phone 
-Study performed in one 
location only, may not 
be generalizable 
Relevance: 
-HPV vaccine was not 
included in the RCT 
- Study was aimed at 
adolescent vaccines  
-Were not able to reach 
after 4 telephone calls, 
important to examine 
other methods: email, 
texting, social media, 
school-based outreach 
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3. significant increased 
rate of IZ (63.3%) 
In multivariate analysis: 
2. OR 2.40 (95% CI 1.51-
3.82) 
3. OR 3.78 (95% CI 1.68-
8.52)  
 
Chao, C., Preciado, M., 
Slezak, J., & Lanfang, 
X. (2014). A 
randomized intervention 
of reminder letter for 
Human Papillomavirus 
vaccine series 
completion. Journal of 
Adolescent Health, 56, 
85-90. Doi: 
10.1016/j.jadohealth. 
2014.08.014 
Randomized 
intervention 
study  
-Female 
patients at 
KPSC 
- had received 
at least 1 dose 
(no more than 
2 doses) or 
HPV 
-between 9-26 
yo at time of 
first HPV  
-12,282 
patients 
identified, 
12,255 were 
randomized, 
after 
randomization 
50 more 
patients were 
found 
ineligible. 
12,205 met the 
inclusion 
criteria   
2 groups: 
-Control group 
received standard 
of care (no 
intervention) (20% 
of participants) 
-Intervention group 
would receive a 
reminder letter 
quarterly for those 
who had not 
completed the HPV 
series (80% of 
participants) 
-Primary outcome was the 
% of females who 
completed the HPV series  
- 3-dose completion rate 
was 56.4% at the end of 
the 12 months for 
intervention group  
- compared to 46.6% in 
the control group (p< .01) 
-Effect of intervention 
greater in patients who 
received first dose at 9-17 
yo (24% relative increase) 
-compared to patients who 
received first dose at 18-
26 yo (18% relative 
increase) 
-Patients who had only 
received 1 dose HPV at 
baseline, 40% in 
intervention and 30% in 
control group completed 
the HPV series 
- 20% of girls and 43% f 
young women who had 
only received 1 dose of 
HPV at baseline, did not 
receive any more doses of 
HPV during the 
intervention period  
-When examined each 
race/ethnicity subgroup, 
increase in completion 
rates were highest in 
blacks (14.3% absolute 
difference), followed by 
Hispanics (11.0%), and 
Asian/Pacific Islanders 
(9.9%) compared to 
whites (7.7%).  
Strengths:  
-Reminder letter sent 
quarterly was effective 
intervention to increase 
HPV completion rates 
-Repeated reminders 
over extended period  
Weaknesses:  
-Magnitude of 
improvement was not 
significant 
-Comparison groups 
were not of equal size 
-Not all reminder letters 
successfully delivered, 
some returned as 
undeliverable (388 or 
4% of letters) 
-Some participants 
terminated membership 
with KPSC and lost to 
follow up (1,052 or 
10% of intervention 
group, and 332 or 14% 
of control group.  
-Completion rates did 
not include HPV 
vaccines 
received/completed 
outside of KPSC, 
reported completion 
rate might be at lower 
limit 
-Study did not 
distinguish siblings, 
having a sibling in 
intervention group may 
have affected patients in 
control group 
Relevance: 
-HPV vaccine was 
included in intervention  
- Addresses/mitigates 
racial/ethnic gaps in 
HPV series completion 
rates 
-Other types of 
interventions should be 
explored 
-More research is 
needed to understanding 
barriers  
 
Suh, C. A, Saville, A., 
Daley, M. F., Glazner, J. 
E., Barrow, J., Stockley, 
… Kempe, A. (2012). 
Effectiveness and net 
cost of reminder/recall 
for adolescent 
immunizations. 
RCT -4 private 
pediatric 
practices, 400 
adolescents in 
each practice  
-Aged 11-18 
yo who have 
2 groups 
- Intervention 
group (2 letters and 
2 telephone calls) 
*1 letter followed 
up with auto dialer 
telephone call, if 
one month later 
-Primary outcome was the 
receipt of more than 1 
targeted vaccine and 
receipt of all targeted 
vaccines with 6 months of 
intervention  
-Secondary outcome 
included completion of 
Strengths:  
- Overall significant 
increase in intervention 
group for each vaccine. 
R/R increased 
immunization rates in 3 
or 4 pediatric practices.  
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Pediatrics, 129(6), 
e1437-1445. Doi: 
10.1542/peds. 
2011-1714 
been seen in 
the last 2 years 
-who had not 
received 1 or 
more of 
vaccines (tdap, 
mcv4, or first 
HPV for 
female 
patients). 
-800 
adolescents to 
each group 
patient still needed 
immunization 
another telephone 
call would be done. 
If one month later 
patient still needed 
immunizations, 
final letter would 
be sent.   
 
- Control group 
(usual care), did not 
include 
reminder/recall 
(R/R) 
vaccine series at 12 
months after intervention 
(Hep A, Hep B, Varicella 
and HPV- females only) 
-751 (94%) of patients in 
intervention group 
received 1 recall phone 
call and 1 recall letter, 34 
(4%) received recall letters 
only, 13 (2%) received at 
least 1 recall call only, and 
2 (<1%) received neither 
recall calls or letters 
-For 91 (11%) of patients, 
recalls were stopped per 
parent request  
-A significantly higher 
percentage of adolescents 
in intervention group 
received at least 1 targeted 
vaccine (p<.001).  
-In 3 practices the 
intervention group had a 
significant higher 
proportion of adolescents 
who received at least 1 
vaccine, in 1 practice there 
was no effect observed 
-Adjusted RR to receive at 
least 1 vaccine was 1.36 
(95% CI 1.21-1.54) 
- Significant higher 
percentage of adolescent 
in intervention group 
received all targeted 
vaccines (P< .001) 
-In 3 practices 
significantly higher 
proportions of adolescents 
in intervention group 
received all targeted 
vaccines, in practice 2 
there was no change 
-Adjusted RR to receive 
all targeted vaccines was 
1.44 (95% CI 1.25-1.67).  
-Overall significant 
increase in intervention 
group for each vaccine, 
(HPV rates were lower 
than other 2 vaccines) 
 
-Also resulted in higher 
UTD rates for other 
vaccines, Hep A and 
Varicella, and higher 
rate of HPV completion 
rate 
- If patients sibling met 
inclusion data also, only 
1 adolescent in 
household was chosen 
to be in study. Sibling 
would get the same 
intervention, but data 
not analyzed 
-Cost analysis of 
intervention showed 
positive net additional 
revenues for 3 practices, 
but 1 practice had a 
loss.  
Weaknesses:  
Overall significant 
increase in intervention 
group for each vaccine, 
but HPV rates were 
lower than other 2 
vaccines 
Relevance: 
-HPV vaccine was 
included in the RCT, 
but only for females 
-Cost benefit analysis 
showed positive net 
revenue for 3 of 4 
practices, suggesting 
intervention is cost 
effective. Only study so 
far that has taken cost 
into account 
Szilagyi, P. G., Schaffer, 
S., Barth, R., Shone, L. 
P., Humiston, S. G., 
Ambrose, S., & 
Averhoff, F. (2006). 
Effect of telephone 
reminder/recall on 
adolescent 
immunizations and 
preventive visits: 
Results from a 
randomized clinical 
trial. Archives of 
Pediatric & Adolescent 
Medicine, 160(2), 157-
163. Doi: 
10.1001/archpedi. 
RCT -Adolescents 
11-14 yo 
- 4 urban 
primary care 
practices in 
Rochester: 
including 2 
pediatric group 
practices, 
hospital based 
pediatric clinic, 
and family 
medicine based 
neighborhood 
health center.  
2 groups 
-Study group.  Was 
sent audiotaped 
telephone 
reminders about a 
scheduled or 
needed 
immunization or 
physical exam.  
Called weekly if no 
response.   
-Control group 
received standard 
care.  
 
-At the end of the 
intervention (18 months), 
study group had higher 
Hep B coverage (3 doses), 
(62.0% vs. 57.8%) 
-Both study and control 
groups increased rates of 
Hep B and Td 
vaccinations, but only 
significant difference was 
in Hep B  
-Intervention was most 
effective during the first 
few months of the study, 
but benefit did not persist 
Strengths:  
-Showed improvement 
in vaccination rates for 
Hep B and Td in the 
short term, but only Hep 
B was significant 
improvement  
- Shows the importance 
of clinics maintaining 
UTD contact 
information for 
patients/parents 
Weaknesses:  
-Did not show 
improvement over the 
long term 
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160.2.157 -seen within 
the last 24 
month 
-Due for annual 
physical, 
tetanus booster 
or Hep B 
vaccination 
-5902 potential 
subjects, 3006 
were eligible 
for 
randomization 
-stratified into 
2 equal age 
groups (11-12 
yo and 13-14 
yo) then 
randomly 
assigned to 
study or 
control group  
-Difficult to reach 
parents/patients by 
phone 
-Older study 
Relevance: 
-HPV vaccine was not 
included in the RCT, 
not yet approved 
- Lack of telephones, 
incorrect telephone 
numbers, changed 
numbers common 
among impoverished 
families – multiple 
telephone numbers vs. 1 
(single) telephone 
number represented less 
mobile group and more 
likely to receive 
intervention 
Szilagyi, P. G., 
Humiston, S. G., 
Gallivan, S., Albertin, 
C., Sandler, M., & 
Blumkin, A. (2011). 
Effectiveness of a 
citywide patient 
immunization navigator 
program on improving 
adolescent 
immunizations and 
preventive care visit 
rates. Archives of 
Pediatric & Adolescent 
Medicine, 165(5),547-
553. Doi:  
10.1001/archpediatrics. 
2011.73 
RCT -Adolescents 
11-15 yo 
-8 primary care 
practices in 
Rochester, 
including: 2 
fed qualified 
community 
health centers, 
2 pediatric 
hospital-based 
clinics, 1 
family 
medicine 
teaching clinic, 
1 hospital-
associated 
medicine-
pediatrics 
practice, and 2 
urban private 
practices.  
-seen within 
the last 2 years 
-7547 
adolescents 
identified and 
randomized  
2 groups 
-Intervention –
tiered protocol. 
Delivered by 
trained patient 
immunization 
navigator. 
-Steps: patient 
tracking, 
reminders/recall 
(telephone + mail), 
home visits,  
- Standard of care 
control- all 
practices routinely 
sent 
letter/telephone 
reminders for 
scheduled visits but 
no active 
reminder/recall 
based on 
vaccinations 
-Primary outcome were 
the immunization rates at 
end of study  
-Secondary outcome were 
preventive care visit rates 
during 12 months and the 
costs  
-Immunization rates at the 
end of the study for all 3 
vaccines combined 
(including HPV for girls) 
were 12-16% higher in 
intervention group 
compared to control 
-Preventive care visit rates 
were 9-17% higher in 
intervention group  
-Intervention had greater 
effects on immunizations 
for girls vs boys (26% 
higher) and for black or 
Hispanic than for whites 
(40% and 27% higher).  
-Intervention had greater 
effect on preventive care 
visits for those without 
previous preventive care 
visits (13% higher).  
-71% intervention group 
received telephone/mail 
reminders, 12% home visit 
 
Strengths:  
-Large scale study, 
included more than 40% 
adolescents in 
Rochester 
-Broad spectrum of 
primary care practices 
- Cost effective: $3.81 
per adolescent per 
month 
-Benefit of tiered 
intervention. More 
intense intervention 
reserved for patients 
who do not respond to 
lower-level 
interventions 
Weaknesses:  
-Inability to distinguish 
impact of different parts 
of tiered intervention 
-Since baseline IZ rates 
were low, benefits of 
intervention may not 
persist as rates increase.  
Relevance: 
-HPV vaccine was 
included in the RCT, for 
females only 
- Study was aimed at 
adolescent vaccines  
-Considered cost  
-RN unable to make 
house calls, new SW 
could be a good 
resource for 
collaboration 
 
Szilagyi, P. G., Albertin, 
C., Humiston, S. G., 
Rand, C. M., Schaffer, 
S., Brill, H., … & 
Stokley, S. (2013). A 
randomized trial of the 
effect of centralized 
reminder/recall on 
immunization and 
RCT -adolescents 
11-17 yo 
-9369 total 
adolescents 
served by 37 
practices 
practices (22 
pediatric, 13 
family 
3 groups  
- intervention: 
mailed letter. Sent 
at 10-week 
intervals for Tdap, 
MCV4 and 
preventive care 
visits (Max 5 
-Main outcome measure 
were immunization rates 
for routine vaccines 
(MCV4, Tdap, HOV) and 
preventive visit rates at 
end of study 
-Secondary outcome 
measures were process 
measures for mailed 
Strengths:  
-Only 56 (6%) of 1431 
mailed reminders were 
returned 
- Siblings allocated to 
the same group 
Weaknesses:  
-Managed care database 
lacked telephone 
IMPROVING RATES OF HPV VACCINATION  
	
41 
preventive care visits for 
adolescents. Academic 
Pediatrics, 13(3), 204-
213. Doi: 10.1016/j.acap 
.2013.01.002 
medicine, 2 
internal 
medicine).  
-4,115 youths 
identified from 
37 primary care 
-no preventive 
care visit 
within 14 
months, 
eligible for 
Tdap, MCV4, 
or HPV.  
reminders in 12 
months) 
For 1st dose HPV 
every 10 weeks, 
and for 2nd and 3rd 
dose every 5 weeks 
(8 max reminders 
per dose) 
-intervention: 
telephone 
reminders. Sent at 
same frequency as 
letters.  
-control (standard 
care from each 
practice, some 
already used 
telephone or mailed 
reminders for 
scheduled visits 
and for those 
behind on 
vaccinations) 
reminders (returned 
letters), and telephone 
reminders (busy, no 
answer, machine), and 
those who opted out. 
-Assessed missed 
opportunities. 
- Immunization rates for 
individual vaccines and 
for all vaccines combined 
were 4-9% greater for 
intervention group 
compared to control 
-22% of adolescents 
missing a vaccine were 
mailed a reminder, 17% 
were telephoned 
-13% of control group 
received all vaccinations 
by end of study 
-Results of two 
interventions were 
significantly different 
compared to control  
-Overall immunization 
rates were 56% for mailed 
reminder group, 53% for 
telephone reminders 
group, and 50% for 
controls group 
-65% of mailed reminder 
group, 63% of telephone 
reminder group and 59% 
of control group patients 
had a preventative care 
visit 
-Preventive visits actually 
declined in the control 
group from 63% to 59% 
-Fewer missed 
opportunities in 
intervention groups 
compared to controls  
number (41%) or a 
“geocodable” address 
(3.6%) 
- 388 (27%) of 
households in telephone 
reminder group did not 
answer or VM answered 
-Challenge is still lack 
of accurate contact 
information- should 
update contact 
information at every 
encounter  
-Baseline 
immunizations were 
lower, benefits of 
intervention decrease as 
rates improve 
Relevance: 
-HPV vaccine was 
included in the RCT 
- Study was aimed at 
adolescent vaccines  
-Also included 
preventive visits  
-Centralized systems by 
managed care 
organizations- may not 
be applicable to project 
since it is too large 
scale. Sutter/PAMF has 
a centralized reminder 
system, but not for 
vaccine only 
appointments(?) 
-Modest cost: $18.78 
per adolescent per year 
for mailed reminders, 
$16.68 per adolescent 
per year for telephone 
reminders 
-ROI is difficult to 
determine d/t multiple 
benefits of added IZs + 
preventive visits, 
potentially accruing 
over the years  
-More intensive tiered 
outreach have greater 
impact, but more costly 
 
 
 
 
 
 
 
 
IMPROVING RATES OF HPV VACCINATION  
	
42 
Appendix B 
 
 
 
IMPROVING RATES OF HPV VACCINATION  
	
43 
 
 
IMPROVING RATES OF HPV VACCINATION  
	
44 
 
 
IMPROVING RATES OF HPV VACCINATION  
	
45 
Appendix C 
“4 Pillars Practice Transformation Program” 
Pillars  Strategies 
1.Convenience 
and Easy Access  
• Use every patient visit type as an opportunity to vaccinate. 
• Offer open access/walk-in vaccination during office hours. 
• Promote simultaneous vaccination 
• Hold express vaccination clinics outside normal office hours where only 
vaccines are offered, with streamlined flow systems for check-in, screening, 
and record keeping. 
• Create a dedicated vaccination station. 
• Extend the influenza vaccination season by vaccinating as soon as supplies 
arrive and continuing to vaccinate as long as flu is circulating in the 
community. 
2. Patient 
Communication  
• Provide information about vaccine preventable diseases at the beginning of 
every visit. 
• Enroll patients in electronic health portal. 
• Train staff to discuss vaccines during routine processes such as vital signs. 
• Discuss the serious nature of vaccine preventable diseases. 
• Promote 100% vaccination rates among staff to set a good example. 
• Use on-hold messages, poster, fliers, electronic message board, website 
posting, and social media to promote vaccination. 
• Reach out by email, phone, text, mail, health portal etc. to recommend 
vaccines that are due and about arrival of influenza vaccine supplies. 
3. Enhanced 
Vaccination 
Systems 
• Ensure sufficient vaccine inventory to handle increased immunizations. 
• Assess vaccination eligibility for every patient encounter by a systematic 
mechanism. 
• Review accurate EMR vaccination record keeping. 
• Update EMR with vaccinations as they are administered. 
• Update EMR with vaccinations given elsewhere. 
• Assess immunizations as part of vital signs. 
• Establish standing order protocols for nursing and other patient care staff to 
vaccinate without an individual physician order. 
• Develop systematic process for vaccinating every person with a vaccination 
need, such as standing orders or pending/queuing an order in the electronic 
health record. 
4. Motivation  • Create a chart to track progress. Set an improvement goal and regularly track 
progress (e.g., daily or weekly). Post the graph of your progress in a 
prominent location and update it regularly. 
• Provide ongoing feedback to staff on vaccination progress at staff meetings or 
through other forms of communications. 
• Create a competitive challenge for the most vaccinations given among your 
staff. 
• Provide rewards for successful results to create a fun-spirited environment. 
(University, 2018) 
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Appendix D 
Lippit’s	phases	of	change	theory	
	
	
(as	cited	in	Mitchell,	G.,	2013)	
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Appendix Q 
 
